European Organisation for Research and Treatment of Cancer - EORTC

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, European Organisation for Research and Treatment of Cancer - EORTC sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).

15 total trials 2 currently recruiting 9 completed later-stage tilt top decile by trial count

European Organisation for Research and Treatment of Cancer - EORTC: 15 sponsored US clinical trials, 2 recruiting.

European Organisation for Research and Treatment of Cancer - EORTC sponsors 15 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 9 completed. 9 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Brain and Central Nervous System Tumors, with 1 trials.

Top-decile sponsor footprint

European Organisation for Research and Treatment of Cancer - EORTC ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 44/100

9 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

15 total, page 1 of 1

RECRUITING Phase 3

Adjuvant Tebentafusp in High Risk Ocular Melanoma

NCT06246149
RECRUITING Phase 3

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

NCT04031677
ACTIVE NOT RECRUITING

Male Breast Cancer: Understanding the Biology for Improved Patient Care

NCT01101425
ACTIVE NOT RECRUITING Phase 3

Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)

NCT00626990
COMPLETED Phase 3

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

NCT03345095
COMPLETED

Diffusion-Weighted MRI for Liver Metastasis

NCT02781935
COMPLETED

Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma

NCT03770468
COMPLETED NA

Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma

NCT01344018
TERMINATED Phase 2

Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma

NCT01189253
COMPLETED Phase 3

Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor

NCT00047125
TERMINATED Phase 2

Radiation Therapy and Fluorouracil Before Surgery in Treating Patients With Primary or Recurrent Bile Duct Cancer

NCT00030511
COMPLETED Phase 3

Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer

NCT00022191
COMPLETED Phase 3

Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00003279
COMPLETED Phase 3

Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count

NCT00003805
COMPLETED Phase 3

Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis

NCT00003031

Phase Distribution

PhaseTrial count
Phase 2 2
Phase 3 9

Therapeutic Areas

Brain and Central Nervous System Tumors 1
Retroperitoneal Sarcoma 1
Liposarcoma 1
Leiomyosarcoma 1

Where European Organisation for Research and Treatment of Cancer - EORTC enrollment is open (later-stage tilt)

2 recruiting of 15 indexed (13% open); 9 completed (60%).

Phase mix: 9 late (III/IV) vs 2 early (I/II) (later-stage heavy).

Top condition: Brain and Central Nervous System Tumors (1 trial), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

European Organisation for Research and Treatment of Cancer - EORTC: open-pipeline peers nationwide

Peers matched on 15 registered trials and 13% open enrollment, not the therapeutic-area sidebar.

European Organisation for Research and Treatment of Cancer - EORTC sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 101520253035 0%10%20%30%40% Total trials Recruiting share European Organisation for Research and Treatment of Cancer - EORTCAllakosArbor Research Collaborative for HealthArena PharmaceuticalsArrowhead PharmaceuticalsChiesi Farmaceutici S.p.A.Dizal PharmaceuticalsEdgewise TherapeuticsEpicentRx
European Organisation for Research and Treatment of Cancer - EORTC sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

European Organisation for Research and Treatment of Cancer - EORTC sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 15 trials (± recruiting share)

Sponsors near 13% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this European Organisation for Research and Treatment of Cancer - EORTC page

15 registered trials is a research-attention snapshot, not an endorsement of European Organisation for Research and Treatment of Cancer - EORTC or any single study.

  • 2 of European Organisation for Research and Treatment of Cancer - EORTC's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Brain and Central Nervous System Tumors is the condition European Organisation for Research and Treatment of Cancer - EORTC studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Brain and Central Nervous System Tumors trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. European Organisation for Research and Treatment of Cancer - EORTC pipeline card: 15 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.